Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report.
ARIA
EAACI
apps
digital health
rhinitis
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
27
03
2023
received:
23
02
2023
accepted:
05
04
2023
medline:
3
7
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1758-1776Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301. doi:10.1016/j.smim.2019.101301
Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039-3068. doi:10.1111/all.14582
Porpodis K, Tsiouprou I, Apostolopoulos A, et al. Eosinophilic asthma, phenotypes-Endotypes and current biomarkers of choice. J Pers Med. 2022;12(7):1093. doi:10.3390/jpm12071093
Diamant Z, Vijverberg S, Alving K, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835-1851. doi:10.1111/all.13806
Radzikowska U, Baerenfaller K, Cornejo-Garcia JA, et al. Omics technologies in allergy and asthma research: an EAACI position paper. Allergy. 2022;77(10):2888-2908. doi:10.1111/all.15412
Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. doi:10.1016/S2213-2600(21)00124-7
Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302-313. doi:10.1164/rccm.201602-0419OC
Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156):190137. doi:10.1183/16000617.0137-2019
Landry V, Coburn P, Kost K, Liu X, Li-Jessen NYK. Diagnostic accuracy of liquid biomarkers in airway diseases: toward point-of-care applications. Front Med (Lausanne). 2022;9:855250. doi:10.3389/fmed.2022.855250
Ogulur I, Pat Y, Ardicli O, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021;76(12):3659-3686. doi:10.1111/all.15089
Bousquet J, Pfaar O, Agache I, et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021;11(4):e12014. doi:10.1002/clt2.12014
eHealth at WHO. 2021 https://www.who.int/ehealth/about/en/
mHealth. New horizons for health through mobile technologies. Global Observatory for eHealth Series. Vol 3. WHO Library Cataloguing-in-Publication Data; 2011 http://www.who.int/goe/publications/goe_mhealth_web.pdf
Anto A, Sousa-Pinto B, Bousquet J. Anaphylaxis and digital medicine. Curr Opin Allergy Clin Immunol. 2021;21(5):448-454. doi:10.1097/ACI.0000000000000764
Bousquet J, Ansotegui IJ, Anto JM, et al. Mobile Technology in Allergic Rhinitis: evolution in management or revolution in health and care? J Allergy Clin Immunol Pract. 2019;7(8):2511-2523. doi:10.1016/j.jaip.2019.07.044
Bousquet J, Hellings PW, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019;143(3):864-879. doi:10.1016/j.jaci.2018.08.049
Bousquet J, Jutel M, Pfaar O, et al. The role of mobile health technologies in stratifying patients for AIT and its cessation. The ARIA-EAACI perspective. J Allergy Clin Immunol Pract. 2021;9(5):1805-1812. doi:10.1016/j.jaip.2021.02.035
FDA-NIH Biomarker Working Group. BEST (Biomarkers, Endpoint S, and Other Tools) Resource. FDA-NIH Biomarker Working Group; 2016.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
Goldsack JC, Coravos A, Bakker JP, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs). NPJ Digit Med. 2020;3:55. doi:10.1038/s41746-020-0260-4
Hodgson DR, Whittaker RD, Herath A, Amakye D, Clack G. Biomarkers in oncology drug development. Mol Oncol. 2009;3(1):24-32. doi:10.1016/j.molonc.2008.12.002
U.S. Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Final guidance document. https://wwwfdagov/media/139088/download 2020.
Vasudevan S, Saha A, Tarver ME, Patel B. Digital biomarkers: convergence of digital health technologies and biomarkers. NPJ Digit Med. 2022;5(1):36. doi:10.1038/s41746-022-00583-z
Pepin JL, Degano B, Tamisier R, Viglino D. Remote monitoring for prediction and Management of Acute Exacerbations in chronic obstructive pulmonary disease (AECOPD). Life (Basel). 2022;12(4):499. doi:10.3390/life12040499
Ku JP, Sim I. Mobile health: making the leap to research and clinics. NPJ Digit Med. 2021;4(1):83. doi:10.1038/s41746-021-00454-z
Sim I. Mobile Devices and Health. N Engl J Med. 2019;381(10):956-968. doi:10.1056/NEJMra1806949
Paving the way for personalized medicine, FDA's role in a new era of medical product development. http://wwwfdagov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421pdf 2013.
Canonica GW, Bachert C, Hellings P, et al. Allergen immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J. 2015;8(1):31. doi:10.1186/s40413-015-0079-7
Bousquet J, Pfaar O, Togias A, et al. 2019 ARIA Care pathways for allergen immunotherapy. Allergy. 2019;74(11):2087-2102. doi:10.1111/all.13805
Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1-12. doi:10.1016/j.jaci.2019.05.031
Louis R, Bureau F, Desmet CJ. Advances toward precision medicine for asthma. Biochem Pharmacol. 2020;179:114081. doi:10.1016/j.bcp.2020.114081
Salter B, Lacy P, Mukherjee M. Biologics in asthma: a molecular perspective to precision medicine. Front Pharmacol. 2021;12:793409. doi:10.3389/fphar.2021.793409
Type 2 diabetes in adults: management. NICE Diabetes Guidance. https://wwwguidelinescouk/diabetes/nice-type-2-diabetes-guideline/252691article. 2022.
American Diabetes Association. 6. Glycemic targets: standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S61-S70. doi:10.2337/dc19-S006
van der Leeuw S, van der Molen T, Dekhuijzen PN, et al. The minimal clinically important difference of the control of allergic rhinitis and asthma test (CARAT): cross-cultural validation and relation with pollen counts. NPJ Prim Care Respir Med. 2015;25:14107. doi:10.1038/npjpcrm.2014.107
Linhares DV, da Fonseca JA, Borrego LM, et al. Validation of control of allergic rhinitis and asthma test for children (CARATKids)-a prospective multicenter study. Pediatr Allergy Immunol. 2014;25(2):173-179. doi:10.1111/pai.12218
Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy. 2010;65(8):1042-1048. doi:10.1111/j.1398-9995.2009.02310.x
Wang Y, Chen H, Zhu R, et al. Allergic rhinitis control test questionnaire-driven stepwise strategy to improve allergic rhinitis control: a prospective study. Allergy. 2016;71(11):1612-1619. doi:10.1111/all.12963
Nathan RA, Dalal AA, Stanford RH, et al. Qualitative development of the rhinitis control assessment test (RCAT), an instrument for evaluating rhinitis symptom control. Patient. 2010;3(2):91-99. doi:10.2165/11318410-000000000-00000
Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-907. doi:10.1034/j.1399-3003.1999.14d29.x
Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549-556. doi:10.1016/j.jaci.2006.01.011
Sousa-Pinto B, Azevedo LF, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy. 2022;77(7):2147-2162. doi:10.1111/all.15199
Anto A, Sousa-Pinto B, Czarlewski W, et al. Automatic market research of mobile health apps for the self-management of allergic rhinitis. Clin Exp Allergy. 2022;52(10):1195-1207. doi:10.1111/cea.14135
Bastl K, Berger U, Kmenta M. Evaluation of pollen apps forecasts: the need for quality control in an eHealth service. J Med Internet Res. 2017;19(5):e152. doi:10.2196/jmir.7426
Bastl M, Bastl K, Dirr L, Berger M, Berger U. Variability of grass pollen allergy symptoms throughout the season: comparing symptom data profiles from the Patient's Hayfever diary from 2014 to 2016 in Vienna (Austria). World Allergy Organ J. 2021;14(3):100518. doi:10.1016/j.waojou.2021.100518
Dramburg S, Perna S, Di Fraia M, et al. Heterogeneous validity of daily data on symptoms of seasonal allergic rhinitis recorded by patients using the e-diary AllergyMonitor(R). Clin Transl Allergy. 2021;11(10):e12084. doi:10.1002/clt2.12084
Tripodi S, Giannone A, Sfika I, et al. Digital technologies for an improved management of respiratory allergic diseases: 10 years of clinical studies using an online platform for patients and physicians. Ital J Pediatr. 2020;46(1):105. doi:10.1186/s13052-020-00870-z
Sousa-Pinto B, Anto A, Berger M, et al. Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities. Clin Transl Allergy. 2022;12(11):e12208. doi:10.1002/clt2.12208
Moore A, Preece A, Sharma R, et al. A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. Eur Respir J. 2021;57(6):2003103. doi:10.1183/13993003.03103-2020
Mosnaim GS, Stempel DA, Gonzalez C, et al. The impact of patient self-monitoring via electronic medication monitor and Mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2021;9(4):1586-1594. doi:10.1016/j.jaip.2020.10.064
Mosnaim GS, Stempel DA, Gonzalez C, et al. Electronic medication monitoring versus self-reported use of inhaled corticosteroids and short-acting beta2-agonists in uncontrolled asthma. J Asthma. 2022;59(10):2024-2027. doi:10.1080/02770903.2021.1996600
Sousa-Pinto B, Sa-Sousa A, Amaral R, et al. Assessment of the control of allergic rhinitis and asthma test (CARAT) using MASK-air. J Allergy Clin Immunol Pract. 2022;10(1):343-345.e2. doi:10.1016/j.jaip.2021.09.012
Bousquet J, Devillier P, Anto JM, et al. Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study. Allergy. 2018;73(8):1622-1631. doi:10.1111/all.13448
Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: the MASK observational pilot study. Allergy. 2018;73(9):1763-1774. doi:10.1111/all.13406
Bedard A, Anto JM, Fonseca JA, et al. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air((R)) app. Allergy. 2020;75(7):1672-1688. doi:10.1111/all.14204
Bedard A, Basagana X, Anto JM, et al. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clin Transl Allergy. 2020;10(1):62. doi:10.1186/s13601-020-00342-x
Bedard A, Sofiev M, Arnavielhe S, et al. Interactions between air pollution and pollen season for rhinitis using Mobile technology: a MASK-POLLAR study. J Allergy Clin Immunol Pract. 2020;8(3):1063-1073.e4. doi:10.1016/j.jaip.2019.11.022
Sousa-Pinto B, Schunemann HJ, Sa-Sousa A, et al. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: the MASK-air(R) longitudinal study. Allergy. 2022;78:968-983. doi:10.1111/all.15574
Bousquet J, Agache I, Aliberti MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2017;73(1):77-92. doi:10.1111/all.13218
Courbis AL, Murray RB, Arnavielhe S, et al. Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018;48(12):1640-1653. doi:10.1111/cea.13230
Sofiev M, Palamarchuk Y, Bedard A, et al. A demonstration project of global Alliance against chronic respiratory diseases: prediction of interactions between air pollution and allergen exposure-the Mobile airways sentinel NetworK-impact of air POLLution on asthma and rhinitis approach. Chin Med J (Engl). 2020;133(13):1561-1567. doi:10.1097/CM9.0000000000000916
Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61-68. doi:10.4137/HSI.S11093
Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27(3):153-155. doi:10.1136/bmjebm-2020-111573
Bousquet J, Arnavielhe S, Bedbrook A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018;8:45. doi:10.1186/s13601-018-0227-6
Sousa-Pinto B, Fonseca JA, Gemicioglu B, et al. Patient-reported outcome measures (PROMs) using the MASK-air(R) app in severe asthma. Allergy. 2022;77(5):1600-1602. doi:10.1111/all.15248
Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. Allergy. 2017;72(10):1475-1484. doi:10.1111/all.13177
Vandenplas O, Suarthana E, Rifflart C, Lemiere C, Le Moual N, Bousquet J. The impact of work-related rhinitis on quality of life and work productivity: a general workforce-based survey. J Allergy Clin Immunol Pract. 2020;8:1583-1591.e5. doi:10.1016/j.jaip.2019.12.033
Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: the MASK study. J Allergy Clin Immunol. 2019;144(1):135-143.e6. doi:10.1016/j.jaci.2019.01.053
Sousa-Pinto B, Filipe Azevedo L, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy. 2021;77:2147-2162. doi:10.1111/all.15199
International Classification of Functioning, Disability and Health (ICF). https://www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health. World Health Organization; 2011.
Woo S, Kim S. Determination of cutoff values for biomarkers in clinical studies. Precis Future Med. 2020;4(1):2-8.
Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy. 2003;58(4):289-294. doi:10.1034/j.1398-9995.2003.00079.x
Baiardini I, Fasola S, La Grutta S, Trucco E, Canonica GW, Braido F. Rhinitis and asthma patient perspective (RAPP): clinical utility and predictive value. J Allergy Clin Immunol Pract. 2022;10(3):846-852 e1. doi:10.1016/j.jaip.2021.10.025
Ansotegui IJ, Braido F, Molinengo G, et al. Cross-cultural adaptation and validation of the RhinAsthma patient perspective (RAPP) in Spanish. Allergol Immunopathol (Madr). 2020;48(2):165-169. doi:10.1016/j.aller.2019.07.006
Todo-Bom A, Braido F, Molinengo G, Loureiro C, Canonica GW, Baiardini I. The Portuguese version of rhinitis and asthma Patient's perspective (RAPP): validation and assessment. Pulmonology. 2020;26(2):73-77. doi:10.1016/j.pulmoe.2018.10.009
Lim MC, Baiardini I, Molinengo G, Navarro-Locsin CG, Canonica GW, Braido F. The cross-cultural validation of the English version of RhinAsthma patient's perspective (RAPP). J Asthma. 2020;57(6):680-686. doi:10.1080/02770903.2019.1590595
Kupczyk M, Baiardini I, Molinengo G, et al. Cross-cultural adaptation and validation of the RhinAsthma patient perspective (RAPP) in the polish population. Postepy Dermatol Alergol. 2020;37(1):97-102. doi:10.5114/ada.2020.93387
Fasola S, Montalbano L, Ferrante G, et al. RAPP-children: a new tool for assessing quality of life in patients with asthma and rhinitis. Clin Exp Allergy. 2020;50(6):662-671. doi:10.1111/cea.13599
Molinengo G, Baiardini I, Braido F, Loera B. RhinAsthma patient perspective: a Rasch validation study. J Asthma. 2018;55(2):119-123. doi:10.1080/02770903.2017.1316391
Braido F, Baiardini I, Stagi E, et al. RhinAsthma patient perspective: a short daily asthma and rhinitis QoL assessment. Allergy. 2012;67(11):1443-1450. doi:10.1111/all.12014
Pfaar O, Alvaro M, Cardona V, Hamelmann E, Mosges R, Kleine-Tebbe J. Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy. 2018;73(9):1775-1783. doi:10.1111/all.13429
Bousquet J, VandenPlas O, Bewick M, et al. The work productivity and activity impairment allergic specific (WPAI-AS) questionnaire using Mobile technology: the MASK study. J Investig Allergol Clin Immunol. 2018;28(1):42-44. doi:10.18176/jiaci.0197
Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127-137. doi:10.1007/s40258-017-0310-5
Remenschneider AK, Scangas G, Meier JC, et al. EQ-5D-derived health utility values in patients undergoing surgery for chronic rhinosinusitis. Laryngoscope. 2015;125(5):1056-1061. doi:10.1002/lary.25054
Sousa-Pinto B, Azevedo LF, Sa-Sousa A, et al. Allergen immunotherapy in MASK-air users in real-life: results of a Bayesian mixed-effects model. Clin Transl Allergy. 2022;12(3):e12128. doi:10.1002/clt2.12128
Sousa-Pinto B, Schunemann HJ, Sa-Sousa A, et al. Comparison of rhinitis treatments using MASK-air(R) data and considering the minimal important difference. Allergy. 2022;77:3002-3014. doi:10.1111/all.15371
Sastre J, Del Cuvillo A, Colas C, et al. Validation of the MASK-air app for assessment of allergic rhinitis. Allergy. 2020;75(11):2958-2961. doi:10.1111/all.14415
Vieira R, Sousa-Pinto B, Cardoso-Fernandes A, et al. The control of allergic rhinitis and asthma test (CARAT): a systematic review of its measurement properties and COSMIN analysis. Clin Transl Allergy. 2022;12:e12194.
Azevedo P. Correia de Sousa J, Bousquet J, et al. control of allergic rhinitis and asthma test (CARAT): dissemination and applications in primary care. Prim Care Respir J. 2013;22(1):112-116. doi:10.4104/pcrj.2013.00012
Domingues M, Amaral R, Fonseca JA, Azevedo P, Correia-de-Sousa J. Assessment of asthma control using CARAT in patients with and without allergic rhinitis: a pilot study in primary care. Rev Port Pneumol. 2016;22(3):163-166. doi:10.1016/j.rppnen.2015.10.014
Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al. Control of allergic rhinitis and asthma test (CARAT) can be used to assess individual patients over time. Clin Transl Allergy. 2012;2(1):16. doi:10.1186/2045-7022-2-16
Jacome C, Pereira R, Almeida R, et al. Validation of app and phone versions of the control of allergic rhinitis and asthma test (CARAT). J Investig Allergol Clin Immunol. 2021;31(3):270-273. doi:10.18176/jiaci.0640
Amaral R, Jacome C, Almeida R, et al. Profiling persistent asthma phenotypes in adolescents: a longitudinal diagnostic evaluation from the INSPIRERS studies. Int J Environ Res Public Health. 2021;18(3):1015. doi:10.3390/ijerph18031015
Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi:10.1183/13993003.02730-2021
Bissell K, Ellwood P, Ellwood E, et al. Essential medicines at the National Level: the global asthma Network's essential asthma medicines survey 2014. Int J Environ Res Public Health. 2019;16(4):605. doi:10.3390/ijerph16040605
Bousquet JJ, Schunemann HJ, Togias A, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy. 2019;9:44. doi:10.1186/s13601-019-0279-2
Quirce S, Sastre J. Occupational asthma: clinical phenotypes, biomarkers, and management. Curr Opin Pulm Med. 2019;25(1):59-63. doi:10.1097/MCP.0000000000000535
Vandenplas O, Godet J, Hurdubaea L, et al. Severe occupational asthma: insights from a multicenter European cohort. J Allergy Clin Immunol Pract. 2019;7(7):2309-2318.e4. doi:10.1016/j.jaip.2019.03.017
Kwon JH, Wi CI, Seol HY, et al. Risk, mechanisms and implications of asthma-associated infectious and inflammatory multimorbidities (AIMs) among individuals with asthma: a systematic review and a case study. Allergy Asthma Immunol Res. 2021;13(5):697-718. doi:10.4168/aair.2021.13.5.697
Tsang KCH, Pinnock H, Wilson AM, Shah SA. Application of machine learning algorithms for asthma management with mHealth: a clinical review. J Asthma Allergy. 2022;15:855-873. doi:10.2147/JAA.S285742
Caimmi D, Baiz N, Tanno LK, et al. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clin Exp Allergy. 2017;47(12):1526-1533. doi:10.1111/cea.13025
Sousa-Pinto B, Eklund P, Pfaar O, et al. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air(R). Clin Transl Allergy. 2021;11(7):e12062. doi:10.1002/clt2.12062
Dunn A, Heggestad E, Shanock L, Theilgard N. Intra-individual response variability as an indicator of insufficient effort responding: comparison to other indicators and relationships with individual differences. J Business Psychol. 2018;33(1):105-121.
Bousquet J, Arnavielhe S, Bedbrook A, et al. The allergic rhinitis and its impact on asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: the MASK study. Allergy. 2018;73(2):505-510. doi:10.1111/all.13307
Bakdash JZ, Marusich LR. Repeated measures correlation. Front Psychol. 2017;8:456. doi:10.3389/fpsyg.2017.00456
Type 2 diabetes in adults: management. NICE guideline [NG28]. https://www.nice.org.uk/guidance/ng28/chapter/Recommendations
Vieira RJ, Pham-Thi N, Anto JM, et al. Academic productivity of Young people with allergic rhinitis: a MASK-air study. J Allergy Clin Immunol Pract. 2022;10(11):3008-3017.e4. doi:10.1016/j.jaip.2022.08.015
Vieira RJ, Sousa-Pinto B, Cardoso-Fernandes A, et al. Control of allergic rhinitis and asthma test: a systematic review of measurement properties and COSMIN analysis. Clin Transl Allergy. 2022;12(9):e12194. doi:10.1002/clt2.12194